Huma is helping UK employers to get their employees back to work quickly and safely. Through a revolutionary app, employees can help prevent COVID-19 from entering the workplace which limits further disruption so businesses can recover faster.
The healthcare industry is built on a reactive rather than proactive model. We are late in diagnosing and intercepting patients with limited to no visibility of the disease progression outside of clinical settings, where chronic disease patients spend more than 95% of their time. Traditional medicine has relied on periodic data/insights generated via clinical visits, lab tests, medical imaging and genomics. With periodic data, it is almost impossible to deliver true proactive/predictive care. We need real time insights to deliver real time healthcare.
Sign up to our newsletters
Receive news and guidance on a range of HR issues direct to your inbox
Huma believes in digital biomarkers, a new category of medicine based on signatures found in the data generated by our bodies – the way we walk, talk, or behave. Digital biomarkers are defined as objective, quantifiable physiological and behavioural data that are collected and measured by means of digital devices such as portables, wearables, implantable or digestible. Whether collected actively through patient engagement and queries or passively via wearables and medical sensors, these signatures or biomarkers not only detect diseases, but also quantify and manage treatments in ways impossible before. Each digital biomarker will be a key part of developing a Digital Medicine, supporting a variety of diseases and delivering true proactive/predictive medicine. A machine that is always on and proactively protecting the health of everyone 24/7.
We have created a platform with 7 pillars to enable partners to discover, validate and commercially launch digital biomarkers and digital medicine for a variety of diseases. We are the catalyst that helps Apple optimise patients for surgery, Tencent track Parkinson’s Disease, J&J screen and diagnose Alzheimer’s, and Bayer aim to predict heart attacks. We have a growing list of digital biomarkers in the Huma pipeline. Our aim is to build, together with our partners, the largest portfolio of digital biomarkers in the world.
Forbes: Huma Teams Up With Cambridge University For Remote Patient Covid-19 Study
Yahoo: Largest survey of bosses and workers on ‘return to work’ attitudes from Huma https://uk.finance.yahoo.com/news/companies-spending-674m-month-welcome-070000556.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAGaDGquvhSY-FWsaBPJK-meLsam_qU1OZJz17DIY_1EqnyYWjjWKNUiLQ9micyOQ0zmNqZWkWo7MKLe98OyJeMArscEXtTi0sSWs5Vy2El2X3HsiQjMNFvOiubk-JgTDpCwLpX3LASjdvU2Ap6wd9EAv1M_qS-dRoUSHcmRXLaWk
Bloomberg: Huma CEO: Working From Home Ultimately Hurts Businesses. https://www.bloomberg.com/news/audio/2020-08-28/huma-ceo-working-from-home-ultimately-hurts-businesses